Covidien releases successful drug-eluting balloon results; Dance Biopharm enters inhaled insulin joint venture;

> Covidien ($COV) released clinical data supporting its drug-coated balloon to treat lower limb blockages in peripheral artery disease patients. More

> Dance Biopharm entered into a joint venture with Harmony Asset to develop an inhaled insulin product in China and other Asian countries. Release

> Rexahn Pharmaceuticals ($RNN) in-licensed a novel oligonucleotide targeted drug delivery platform from Ohio State University, which has shown the ability to deliver compounds to cancer tumors in preclinical trials. Release

> Highly customizable coatings of foam-like polymers developed at the University of Rochester may be used for drug delivery, getting drugs into hard-to-reach places. Release

> Alliqua showed successful preclinical results for its investigational Lidocaine transdermal patch that compare favorably to current versions available on the market. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.